Jubilant Pharmova share news, announcements and annual reports
NSE: JUBLPHARMABSE: 530019Pharmaceuticals & BiotechnologySmall Cap
Jubilant Pharmova Limited · Formerly Jubilant Life Sciences · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jun 1981 on BSE, Jun 2003 on NSE
Last close ₹923.80down ₹22.20 (2.35%)BSE ₹924.70
Share price at the NSE close on 30 Oct 2026. Previous close ₹946.00.
30 Oct: open ₹946.00, high ₹951.80, low ₹920.00
52-week range of traded prices to 30 Oct 2026
₹786.05Low, 9 Mar 2026₹1,183.00High, 4 Nov 2025
- Next results date: the board meets on 13 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹14,714 Cr422nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 41.79
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹59 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 35.78
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.07
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.54%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 5.3%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹59 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 6.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 7.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.45
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 56,22937.1% delivered
Jubilant Pharmova disputes and clarifications
21 filed, newest first.
May 2026
Dec 2025
Oct 2024
Sep 2024
10 Sep · Legal
The exchange asked on 9 Sep 2024
Apr 2024
5 Apr · Legal
The exchange asked on 4 Apr 2024
Dec 2022
12 Dec · Legal
The exchange asked on 9 Dec 2022
Jul 2022
8 Jul · Legal
The exchange asked on 7 Jul 2022
Mar 2019
22 Mar · Legal
The exchange asked on 20 Mar 2019
Feb 2019
Feb 2018
1 Feb · Legal
Exchange has sought clarification from the Company with respect to news item captioned "SEBI Fines Jubliant Life, Senior Officials" In this regard, Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company is aware of any information that has not been announced to the Exchanges under regulation 30 of Listing Regulations. The response from the Company is awaited.
Apr 2017
27 Apr · Legal
Exchange has sought clarification from the Company with respect to news item captioned "Jubilant Life Sciences considering Singapore listing for pharma unit" . In this regard, Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company is aware of any information that has not been announced to the Exchanges under regulation 30 of Listing Regulations. The response from the Company is awaited.
Nov 2016
9 Nov · Legal
Exchange has sought clarification from Jubilant Life Sciences Limited with respect to announcement dated 09-Nov-2016, regarding "Jubilant Life Sciences Limited has informed the Exchange regarding Issuance of Commercial Papers of Rs. 50 crore.".On basis of above the Company is required to clarify following:1. Whether proposed to be listed? If yes, name of the stock exchange(s);2. Tenure of the instrument - date of allotment and date of maturity;3. Coupon/interest offered, schedule of payment of coupon/interest and principal;4. Charge/security, if any, created over the assets;5. Special right/interest/privileges attached to the instrument and changes thereof;6. Delay in payment of interest / principal amount for a period of more than three months from the due date or default in payment of interest / principal;7. Details of any letter or comments regarding payment/non-payment of interest, principal on due dates, or any other matter concerning the security and /or the assets along with its comments thereon, if any;The response of the Company is awaited.
Sep 2016
26 Sep · Legal
Exchange has sought clarification from Jubilant Life Sciences Limited with respect to announcement dated 23-Sep-2016, regarding "Jubilant Life Sciences Limited has informed the Exchange that the Board of Directors of company material wholly owned subsidiary, Jubilant Pharma Limited ("JPL") has, at its meeting held on September 23, 2016, approved the proposal to launch a benchmark offering of unsecured high yield bonds (the "Notes") outside India by JPL, under Regulation S of the US Securities Act. The Notes are proposed to be listed on the Singapore Exchange Securities Trading Limited.".On basis of above the Company is required to clarify following:1. Type of issuance (further public offering, rights issue, depository receipts (ADR/GDR), qualified institutions placement, preferential allotment, etc);2. Total number of securities proposed to be issued or the total amount for which the securities will be issued (approximately);The response of the Company is awaited.
Jul 2015
10 Jul · Legal
Significant volume movement has been observed in Jubilant Life Sciences Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Jubilant Life Sciences Limited has vide its letter inter-alia stated, "that we do not have any information under clause 36 of the Listing Agreement or otherwise to disclose/share with the stock exchanges."
Feb 2014
6 Feb · Legal
Exchange had sought clarification from Jubilant Life Sciences Limited with respect to a news item captioned "Jubilant May Sell Chemical Business to Reduce Debt". The Company has clarified that the news is "Incorrect, speculative and baseless. The management has also denied this and the Management response is carried in the same article which is quoted hereunder: 'Jubilant, however, termed the information speculative . The management does not comment on any such speculative and baseless statements, the group said in an emailed response to a query on the development.'"
Oct 2013